Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33527198 | 0.84 | KCNQ4 (0.36) | AAK1KCNQ4KCNQ5CTSSCTSK | |
| SCHEMBL33526231 | 0.83 | CTSS (0.36) | AAK1KCNQ4KCNQ5CTSSCTSK | |
| SCHEMBL33526532 | 0.83 | KEAP1 (0.38) | AAK1KCNQ4KCNQ5CTSSCTSK | |
| SCHEMBL23105674 | 0.81 | P2RX7 (0.48) | AAK1PKMP2RX7CTSSCTSK | |
| SCHEMBL3635747 | 0.79 | NQO2 (0.49) | MTNR1AMTNR1BP2RX7MEN1HTT | |
| SCHEMBL30114546 | 0.78 | AAK1 (0.38) | AAK1NPC1RAB9A | |
| SCHEMBL33526461 | 0.76 | TSHR (0.41) | MEN1KMT2A | |
| SCHEMBL33526561 | 0.75 | DDB1 (0.38) | AAK1KCNQ4KCNQ5KMT2A | |
| SCHEMBL33526061 | 0.75 | KCNQ4 (0.35) | AAK1KCNQ4KCNQ5MEN1HTT | |
| SCHEMBL7005425 | 0.74 | IDO1 (0.38) | MTNR1AMTNR1BP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | AAK1 2749/4885PKM 3636/4885MTNR1A 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.